Aktiesnakken — Juni 2013
-
Det paradoksale er jo at gobe jobtal vil sænke aktiekurserne
-
Fordi markedet så vil indregne at FED strammer pengepolitiken
-
Nej. Men pt. er der jo så mange penge placereret i obligationer med lave renter at når de skal flyttes over i aktien stiger aktierne
-
Mornings - og ligeledes tak for sidst herfra.
-
Veloxis åbner direkte med udbud i 0,62. Gen ser også pæn ud
-
Gen skal bare lige lave et luk over 220 her i weekenden
-
Velo i 0,62. Den gør klar til endnu en test af 0,7
-
Dog ingen omsætning pt.
-
Prøv at se de skriverier der er om Ibrutinib. Virker som om det stof nærmest kan kurere alle cancerformer http://oncology.healthace.com/052013/oncology_report_052013b.pdf
-
Mine Pharmacyclics aktier ryger ingen steder foreløbigt. Det kan blive det bedst sælgende cancerdrug ever.
-
GILD reported 96% response rate and 93% 2-year PFS for the
combination for idelalisib + Rituxan in first line elderly CLL. While very impressive, the monotherapy data for PCYC’s
ibrutinib was similar (96% PFS at 26 months). If these two regimens are ultimately used sequentially, the treatment lives
of CLL patients could be extended significantly, and turn CLL it into a chronic treatment market. -
med en markedsværdi på usd 6,3b, må man også sige, at der allerede er taget hul på festen
-
havde man dog bare købt sig ind for 3-4 år siden...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind